The Royal Marsden has announced the launch of MyTrack™ Myeloma, the world’s first fully integrated patient pathway for multiple myeloma. This innovative, patient-centred approach brings together leading-edge innovation in advanced diagnostics and clinical expertise to transform how multiple myeloma is understood, monitored, managed and treated, with the goal of significantly improving the patient experience.
The MyTrack Myeloma pathway is initially available to private patients, with Bupa the first health insurer to cover the treatment for its customers with cancer cover. The Royal Marsden’s ambition is to work with the NHS to bring this pioneering pathway to more patients in the future.
Multiple myeloma is an incurable cancer of the plasma cells, with around 6,000 people diagnosed every year in the UK. Patient communities worldwide have consistently highlighted the importance of more personalised approaches to care – including the possibility of treatment breaks, which can improve quality of life and reduce side effects from ongoing therapy. However, standard diagnostic tools do not always provide sufficient insight into the cancer’s behaviour, such as aggressiveness, likelihood of relapse, or suitability for treatment pauses. As multiple myeloma varies widely between patients, identifying those who may safely benefit from treatment breaks requires precise tumour profiling and highly sensitive monitoring. MyTrack Myeloma addresses this gap by integrating advanced diagnostic technologies into a single, coordinated pathway.
The MyTrack Myeloma diagnostic pathway and associated tests will be available from early summer 2026. For further information, including pricing details and how to request tests, please contact ClinicalGenomics_PP@rmh.nhs.uk or visit royalmarsden.nhs.uk/MyTrackMyeloma.
